Corcept Therapeutics Incorporated (CORT) Stock Analysis
A live, multi-source view of Corcept Therapeutics Incorporated (CORT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Sector: Healthcare · Industry: Biotechnology · United States · 730 employees · corcept.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Corcept Therapeutics Incorporated (CORT) had a market capitalization of $12.07B, a trailing P/E of 248.0 (forward 25.4) and a beta of 0.45; the shares traded in a 52-week range of $28.66 – $126.38 (58.4% over the year).
- Market cap
- $12.07B
- Enterprise value
- $11.89B
- Trailing P/E
- 248.0
- Forward P/E
- 25.4
- PEG ratio
- 0.81
- Price / book
- 17.07
- EPS (trailing)
- $0.45
- EPS (forward)
- $4.40
- Payout ratio
- 0.0%
- 52-week range
- $28.66 – $126.38
- 52-week change
- 58.4%
- Beta
- 0.45
- Average volume
- 1.1M
- Shares outstanding
- 108.1M
- Short % of float
- 11.56%
- Profit margin
- 6.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Corcept Therapeutics Incorporated (CORT) last closed at $111.62 (the last completed close before that scan).
Technicals at the scan: RSI 50 (neutral territory), price -3.8% versus its 20-day average, 20-day versus 50-day average spread +11.4%, MACD histogram -1.89.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 70/100.
Next scheduled company event: in 57 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of CORT; corporate insiders filed 0 buys and 8 sells (2 distinct filers, latest disclosure 2026-07-17). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: James N. Wilson (0B/4S), Atabak Mokari (0B/4S). Who is trading what
RapidTradeView pick record
CORT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Corcept Therapeutics Incorporated (CORT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CORT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.